. Semi--High throughput Synergy Screen (sHTSS) (Primary assay) and checkerboard (Secondary assay) --Schematic representation. (A) 96--or 384--well plate format was used to identify hits (secondary compounds) that act in synergy with a drug of interest (primary compound, PC). Up to ten (in 96--well format) or eleven (in 384--well format) secondary compounds are assayed in a serial dilution dose response format in the absence or the presence of sub--MIC concentrations of the PC. The MIC of the PC (MIC PC ), previously determined, was used in the plate design to define PC sub--MIC concentrations. In addition, MIC PC is internally determined for every 96--or 384--plate to assess the actual sub--MIC concentration in the test plate. Pink represents growth. Blue represents growth inhibition. Yellow crosses indicate synergistic combinations. Interactions at 1/2xMIC of PC were not considered (384--plate layout) since the primary compound exhibited strong activity alone. CT--, negative control (no cells, no drugs); CT+, positive control (cells, no drugs). (B) The checkerboard assay was used for synergistic interaction studies. In a 384--well plate format, two dimensional arrays of serial dilutions of up to four test compounds were introduced to exponentially growing cultures of M. tuberculosis. The fractional inhibitory concentration index (FICI) was used to determine whether paired combinations exert inhibitory effects that were more than the sum of their effects alone (FICI <0.5; synergy). Upper left and lower right represent typical appearance profiles of a synergistic combination while upper right and lower left indicate no interaction.
. Rifampicin accumulation in M. bovis BGC. (A) Rifampicin (RIF) at 1 and 10 µg/mL was added to cell cultures incubated at 4 or 37˚C. A temperature--dependent active rifampicin accumulation profile was observed. Accumulation of rifampicin in cultures supplemented with 10 µg/mL did not yield proportional intracellular levels of rifampicin compared to the lower 1 µg/mL rifampicin concentration, indicating a saturated active uptake system. High dose rifampicin (10 µg/mL) reduced cell viability under the assay conditions. A low dose of 1 µg/mL rifampicin incubated at 37˚C was selected for further accumulation studies. (B) Cells were pre--treated overnight in the presence of different beta--lactam synergistic partners before the rifampicin accumulation assay. The presence of beta--lactams increased accumulation levels similar to those observed in the presence of ethambutol. A, amoxicillin; E, ethambutol; F, faropenem; H, isoniazid; M, meropenem; R, rifampicin; V, clavulanate; X, cefadroxil. B.
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Repurposing clinically approved cephalosporins for tuberculosis therapy Ramón--García et al. Table S1 . Strains and compounds used in this study. Table S2 . Rifampin and ethambutol synergy screen hits against M. bovis BCG. Hits were identified as those compounds whose MIC values decreased at least 4--fold in the presence of 1/4xMIC and/or 1/8xMIC concentrations of either rifampin or ethambutol. Hits were prioritized as follows: (i) a 4--fold MIC reduction in the "1/4xMIC" and/ or "1/8xMIC" group compared to "no primary compound" group; (ii) we excluded those compounds exhibiting MIC reductions higher than 128--fold or with fold--reduction ratios "1/4 vs. 1/8" higher than 64--fold (these were considered as artefacts); and finally, (iii) hits with escalating dose response, i.e. higher MIC fold reduction to untreated in the "1/4xMIC" group compared to the "1/8xMIC" group. MIC RIF = 0.03125 µg/mL; MIC EMB = 2 µg/mL. "400" values are assigned arbitrarily and not experimentally confirmed, only used for calculation purposes. Sy, synergy; P, potentiation; N.I., no interactions; Sy*, data from Ramón--García et al. Table S5 . Synergistic interactions between rifamycins, beta--lactams and other cell--wall targeting compounds. Fold reduction indicates the change in MIC of the beta--lactam in the presence of 1/4xMIC of the rifamycin compared to the MIC of the beta--lactam alone. MIC RIF = 16 ng/mL; MIC RPT = 4 ng/mL; MIC RBT = 2 ng/mL RIF, rifampicin; RPT, rifapentine; RBT, rifabutin. Table S6 . Pharmacological properties of oral cephalosporins. Data from John Hopkins ABX guide: http://www.hopkinsguides.com/hopkins/index/Johns_Hopkins_ABX_Guide/All_Topics/A. Table S7 . Amoxicillin plus beta--lactams against M. tuberculosis H37Rv and M. tuberculosis H37Rv H526D (RIF resistant). Fold reduction indicates the change in MIC of the compound in the combination compared to the activity of the compound alone. AMX, amoxicillin; CFX, cefadroxil; CLV, clavuanate; FAR, faropenem; MER, meropenem. FICI, fractional inhibitory concentration index of the combination. A FICI ≤ 0.5 indicates synergism. The closer the value to zero the stronger the synergistc effect of the combination. 
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